Evidence map›Paper›PMID 40057935›Full record

SynthesisInternational journal of hematology2025

Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.

Barbara Abreu Lopez, Joanne Arvelaez Pascucci, Safiya Mohamed Ramzy, Shivani Mehta, Sami Sami Daniel, Rishita Dave, Insiya Rampurawala, Lakshmi Sree Pugalenthi, Dhanuddara Kandambige, Victor Sebastian Arruarana and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Barbara Abreu LopezUniversidad De Carabobo, Naguanagua, Venezuela.
Joanne Arvelaez PascucciUniversidad Central de Venezuela, Caracas, Venezuela.
Safiya Mohamed RamzyInternational Medical University, Dubai, United Arab Emirates.
Shivani MehtaWashington University of Health and Science, Columbus, USA.
Sami Sami DanielAmerican University of the Caribbean School of Medicine, Miramar, USA.
Rishita DaveUniversity of Medicine and Health Sciences, New York, USA.
Insiya RampurawalaJagadguru Sri Shivarathreeshwara Medical College, Mysore, India.
Lakshmi Sree PugalenthiMercy Catholic Medical Center, Darby, PA, USA.
Dhanuddara KandambigeKursk State Medical University, Kursk, Russia.
Victor Sebastian ArruaranaBrookdale Hospital, Brooklyn, NY, USA.
Ernesto Calderon MartinezThe University of Texas Health Science Center at Houston, Houston, TX, USA. Ernestocalderon.mtz@gmail.com.ORCID http://orcid.org/0000-0003-2237-9536

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEssential thrombocythemia (ET) is a myeloproliferative neoplasm commonly treated with hydroxyurea, while anagrelide is a second-line option. Although anagrelide has thrombocyte-specific action, its comparative efficacy remains debated. This systematic review and meta-analysis aimed to measure platelet reduction, thromboembolic events, and adverse events.

methodsA systematic search of PubMed, Cochrane, Web of Science, Scopus, EMBASE, and CINAHL databases up to October 6, 2024, was conducted following the PRISMA guidelines. Randomized controlled trials and cohort studies comparing anagrelide and hydroxyurea were included.

resultsSix studies with 1555 participants met the inclusion criteria. Anagrelide was associated with significantly lower platelet counts than hydroxyurea (MD - 65.22; 95% CI - 80.78 to - 49.66; p < 0.01; I2 = 0%), but no significant difference in thrombohemorrhagic events (RR 1.34; 95% CI 1.10 to 1.62; p < 0.01; I2 = 12.5%). In single-arm analysis, JAK-positive patients showed a higher incidence of thrombotic events (0.23; 95% CI 0.14-0.35) than JAK-negative patients (0.10; 95% CI 0.08-0.13). Adverse event rates varied (RR 1.37; 95% CI 0.37-5.12; I2 = 94.9%).

conclusionAlthough comparative analyses against hydroxyurea have demonstrated the efficacy of anagrelide for platelet reduction in ET, its higher bleeding risk requires caution, especially in patients with risk factors. Further studies are needed to confirm long-term safety and refine dosing.

Indexed as

Platelet Aggregation InhibitorsQuinazolinesThrombocythemia, EssentialHumansHydroxyureaPlatelet CountRandomized Controlled Trials as TopicTreatment OutcomeanagrelideHydroxyureaPlatelet Aggregation InhibitorsQuinazolinesAnagrelideEssential thrombocythemiaEssential thrombocytosis

Identifiers

PMID40057935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.